A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

BACKGROUND: PG545 (pixatimod) is a novel immunomodulatory agent, which has been demonstrated to stimulate innate immune responses against tumours in preclinical cancer models. METHODS: This Phase I study investigated the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary effica...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Dredge, Keith, Brennan, Todd V., Hammond, Edward, Lickliter, Jason D., Lin, Liwen, Bampton, Darryn, Handley, Paul, Lankesheer, Fleur, Morrish, Glynn, Yang, Yiping, Brown, Michael P., Millward, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931096/
https://ncbi.nlm.nih.gov/pubmed/29531325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0006-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky